Skip to main content

Gene variant and glucose metabolism

Feb. 18, 2021, 10:00 AM

by Leigh MacMillan

GLP-1 (glucagon-like peptide-1) increases glucose-mediated insulin secretion. GLP-1 receptor agonists and DPP-4 inhibitors, which prevent GLP-1 inactivation, are widely used to treat type 2 diabetes mellitus. 

Mona Mashayekhi, MD, PhD, and colleagues explored whether a particular genetic variant in the GLP-1 receptor gene affected the metabolic response to a meal and to DPP-4 inhibition. They performed mixed meal studies in individuals with type 2 diabetes and hypertension after 7-day treatment with placebo and the DPP-4 inhibitor sitagliptin. 

The researchers report in Diabetes, Obesity and Metabolism that individuals with the GA/AA variant have decreased glucose excursion — spikes in blood sugar levels — and increased markers of insulin secretion after a meal compared to those with the GG variant. GG individuals, however, benefit most from the DPP-4 inhibitor. 

The findings support further study of the relationship between GLP-1 receptor genotype and therapies that modulate GLP-1 signaling, particularly as this class of agents becomes more broadly prescribed.

This research was supported by the National Institutes of Health (grants HL125426, DK007061, GM007569, TR001879, TR000445) and American Heart Association. 

Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
VUMC Voice